Significance of CAR T-Cell Therapy in Aggressive B-Cell Lymphoma Treatment
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 30 April 2026 | Viewed by 2086
Special Issue Editor
Special Issue Information
Dear Colleagues,
Recently FDA-approved, patients who have relapsed non-Hodgkin and Hodgkin lymphomas can be treated with anti-CD19 CAR-T therapy. Extensive basic and translational research provides insights into the efficacy, toxicity, and potential resistance mechanisms of these therapies. While CAR-T therapy offers significant clinical benefits, efforts to enhance its efficacy and reduce its toxicity are ongoing.
This Special Issue aims to publish research articles and reviews on the following topics:
- Current updates on the efficacy and immune-related adverse events of the six CAR-T therapies that have been FDA-approved for treating refractory and relapsed lymphomas, such as diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, high-grade B-cell lymphoma, transformed follicular lymphoma, and primary/secondary central nervous system lymphoma.
- Preclinical or clinical trial studies on combination therapies with CAR-T cells.
Novel target discovery and multidimensional omics data analyses of the lymphoma microenvironment and CAR-T persistence in aggressive B-cell lymphoma.
Dr. Wing Keung Chan
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- CAR-T therapy
- non-hodgkin lymphoma
- hodgkin lymphoma
- CAR-T persistence
- immune-related adverse events (irAEs)
- resistance mechanisms
- combination therapy
- tumor microenvironment
- multiomics data analysis
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
